Functional intronic variant of <i><scp>SLC</scp>5A10</i> affects <i><scp>DRG</scp>2</i> expression and survival outcomes of early‐stage non‐small‐cell lung cancer

Mi Jeong Hong, Seung Soo Yoo, Jin Eun Choi, Hyo‐Gyoung Kang, Sook Kyung, Jang Hyuck Lee, Won Kee Lee, Jaehee Lee, Shin Yup Lee, Seung Ick,

Cancer Science · 2018 · 12 citations · 21 references

DOIFull text

Open access

Concepts

Abstract

Regulome DB is a new tool that can predict the regulatory function of genetic variants. We applied Regulome DB in selecting putative functional variants and evaluated the relationship between these variants and survival outcomes of surgically resected non‐small‐cell lung cancer. Among the 244 variants studied, 14 were associated with overall survival ( P &lt; 0.05) in the discovery cohort and one variant (rs2257609 C&gt;T) was replicated in the validation cohort. In the combined analysis, rs2257609 C&gt;T was significantly associated with worse overall and disease‐free survival under a dominant model ( P = 2 × 10 −5 and P = 0.001, respectively). rs2257609 is located in the SLC 5A10 intron, but Regulome DB predicted that this variant affected DRG 2 , not SLC 5A10 expression. The expression level of SLC 5A10 was not different with the rs2257609 genotype. However, DRG 2 expression was different according to the rs2257609 genotype ( P trend = 0.03) and was significantly higher in tumor than in non‐malignant lung tissues ( P = 1 × 10 −5 ). Luciferase assay also showed higher promoter activity of DRG 2 in samples with the rs2257609 T allele ( P &lt; 0.0001). rs2257609 C&gt;T affected DRG 2 expression and, thus, influenced the prognosis of early‐stage non‐small‐cell lung cancer. This study was approved by the Institutional Review Broad of Kyungpook National University of Hospital (Approval No. KNUMC 2014‐04‐210‐003).

References

21